marimastat

01/01/2000 - "Marimastat is a synthetic MMPI which has been investigated in clinical studies of patients with advanced cancers. "
09/01/1997 - "The MMP inhibitor, Marimastat, showed remarkable prolongation of the life span of patients with pancreatic tumors in clinical trials."
10/01/2010 - "[(18)F]Marimastat-aryltrifluoroborate localized to the tumors, with labeling being blocked in control animals first loaded with >10-fold excess unlabeled marimastat. "
10/01/2010 - "Novel matrix metalloproteinase inhibitor [18F]marimastat-aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer."
01/01/2009 - "Chemoradiation + marimastat therapy had delayed tumor growth, compared to the chemoradiation alone. "

07/01/2006 - "Because raised matrix metalloprotease (MMP) levels are associated with glioma invasion and angiogenesis, we tested the efficacy of marimastat (MT) an orally active drug that can reduce MMP levels, in patients with gliomas. "
12/01/2002 - "Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma."
08/01/2013 - "Of all the inhibitors tested, we found that Marimastat not only inhibits the expression of MMP14 in U87 and U251 glioma cells, but also induces cell cycle arrest. "
12/01/2002 - "To assess the outcome of high central dose Gamma Knife radiosurgery plus marimastat in patients with recurrent malignant glioma. "
10/01/2006 - "Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status."

07/01/2006 - "Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation."
01/01/2003 - "Results from the marimastat 131 trial in patients with glioblastoma, for example, indicated that marimastat was no better than placebo at prolonging survival in these cancer patients. "
03/01/2002 - "Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme."
01/01/2003 - "Marimastat has been in pivotal phase III trials in glioblastoma, breast, ovarian and small and non-small cell lung cancer, but these trials have all been discontinued because marimastat failed to show superior efficacy over either standard chemotherapy or placebo. "
03/01/2003 - "The metalloproteinase inhibitor marimastat with temozolomide has given the best results to date in phase II trials, increasing the rate of 6-month progression-free survival for recurrent glioblastoma multiforme and anaplastic gliomas. "

01/01/2010 - "We hypothesized that treatment with a broad-spectrum MMP and TACE-inhibitor (Marimastat) would ameliorate injury and inflammation, leading to decreased fibrogenesis during repeated hepatotoxin-induced liver injury. "
07/01/2011 - "Long-term administration of non-selective matrix metalloproteinase (MMP) inhibitors, such as marimastat, in humans elicits musculoskeletal syndrome (MSS), a syndrome characterized by joint damage including pain, stiffness, and inflammation. "
06/17/2002 - "Marimastat treatment was associated with the development of musculoskeletal pain and inflammation. "
01/01/2010 - "Marimastat-treated animals demonstrated significantly attenuated liver injury and inflammation but a 25% increase in collagen deposition. "
11/01/1999 - "Dosing rats with TNBS-induced colitis using sulphasalazine or marimastat produced a significant reduction in tissue injury and inflammation."

01/01/2003 - "British Biotech has also conducted a phase III placebo-controlled study of marimastat as monotherapy in patients with inoperable gastric cancer at 37 centres throughout Europe. "
06/17/2002 - "Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial."
09/01/2000 - "There have, however, been some successes with perhaps the clearest indication of efficacy being seen in the results of a Phase III trial of marimastat in patients with advanced gastric cancer. "
01/01/1999 - "Small phase II studies have suggested potential activity in pancreatic and gastric cancer and have demonstrated the safety of combining cytotoxic chemotherapeutic agents with marimastat. "
05/01/1999 - "[Antitumor effect of a matrix metalloproteinase inhibitor, TA-2516 (Marimastat), on a nude mouse model of intraperitoneal seeding of stomach cancer]."